| Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, ... New England Journal of Medicine 377 (26), 2531-2544, 2017 | 5520 | 2017 |
| Apalutamide treatment and metastasis-free survival in prostate cancer MR Smith, F Saad, S Chowdhury, S Oudard, BA Hadaschik, JN Graff, ... New England Journal of Medicine 378 (15), 1408-1418, 2018 | 1457 | 2018 |
| Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance MR Smith Oncogene 22 (47), 7359-7368, 2003 | 1016 | 2003 |
| MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies GS Choudhary, S Al-Harbi, S Mazumder, BT Hill, MR Smith, J Bodo, ... Cell death & disease 6 (1), e1593-e1593, 2015 | 393 | 2015 |
| Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a … A Advani, B Coiffier, MS Czuczman, M Dreyling, J Foran, E Gine, ... Journal of Clinical Oncology 28 (12), 2085-2093, 2010 | 362 | 2010 |
| Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma JP Leonard, AS LaCasce, MR Smith, A Noy, LR Chirieac, SJ Rodig, ... Blood, The Journal of the American Society of Hematology 119 (20), 4597-4607, 2012 | 351 | 2012 |
| NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas AD Zelenetz, JS Abramson, RH Advani, CB Andreadis, JC Byrd, ... Journal of the National Comprehensive Cancer Network: JNCCN 8 (3), 288-334, 2010 | 325 | 2010 |
| A gain-of-function mutation in the sodium channel gene Scn2a results in seizures and behavioral abnormalities JA Kearney, NW Plummer, MR Smith, J Kapur, TR Cummins, SG Waxman, ... Neuroscience 102 (2), 307-317, 2001 | 298 | 2001 |
| Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the … T Prebet, Z Sun, ME Figueroa, R Ketterling, A Melnick, PL Greenberg, ... Journal of Clinical Oncology 32 (12), 1242-1248, 2014 | 261 | 2014 |
| The New Bisphosphonate, Zometa® (Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate A Lipton, E Small, F Saad, D Gleason, D Gordon, M Smith, L Rosen, ... Cancer investigation 20 (sup2), 45-54, 2002 | 258 | 2002 |
| Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin’s lymphoma E Dotan, C Aggarwal, MR Smith Pharmacy and Therapeutics 35 (3), 148, 2010 | 244 | 2010 |
| Utilization of fine‐needle aspiration cytology and flow cytometry in the diagnosis and subclassification of primary and recurrent lymphoma NA Young, TI Al‐Saleem, H Ehya, MR Smith Cancer Cytopathology: Interdisciplinary International Journal of the …, 1998 | 219 | 1998 |
| Immunotherapy of cancer H Borghaei, MR Smith, KS Campbell European journal of pharmacology 625 (1-3), 41-54, 2009 | 217 | 2009 |
| Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases MR Smith, S Biggar, M Hussain Cancer research 55 (12), 2640-2644, 1995 | 206 | 1995 |
| Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed/refractory multiple myeloma or lymphoma JJ Shah, AJ Jakubowiak, OA O'Connor, RZ Orlowski, RD Harvey, ... Clinical Cancer Research 22 (1), 34-43, 2016 | 192 | 2016 |
| Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy. DP Kelsen, B Minsky, M Smith, J Beitler, D Niedzwiecki, D Chapman, ... Journal of Clinical Oncology 8 (8), 1352-1361, 1990 | 186 | 1990 |
| A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma A Younes, JM Vose, AD Zelenetz, MR Smith, HA Burris, SM Ansell, J Klein, ... British journal of cancer 103 (12), 1783-1787, 2010 | 172 | 2010 |
| Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study … L Fayad, F Offner, MR Smith, G Verhoef, P Johnson, JL Kaufman, ... Journal of Clinical Oncology 31 (5), 573-583, 2013 | 168 | 2013 |
| Memory decline in healthy older people: implications for identifying mild cognitive impairment A Collie, P Maruff, R Shafiq-Antonacci, M Smith, M Hallup, PR Schofield, ... Neurology 56 (11), 1533-1538, 2001 | 152 | 2001 |
| Phase II multicenter study of oblimersen sodium, a Bcl‐2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‐cell non‐Hodgkin lymphoma B Pro, B Leber, M Smith, L Fayad, J Romaguera, F Hagemeister, ... British journal of haematology 143 (3), 355-360, 2008 | 133 | 2008 |
